Dexcom (DXCM) Shares Outstanding (Weighted Average) (2010 - 2026)

Dexcom (DXCM) has 17 years of Shares Outstanding (Weighted Average) data on file, last reported at $385.1 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $385.1 million, down 1.53% year-over-year; the trailing twelve-month figure through Mar 2026 was $385.1 million (down 1.53% YoY), and the FY2025 annual result was $390.2 million, down 0.86% from the prior year.
• Shares Outstanding (Weighted Average) fell to $385.1 million in Q1 2026 per DXCM's latest filing, from $390.2 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $394.8 million in Q2 2024 and troughed at $385.1 million in Q1 2026.
• A 5-year average of $389.9 million and a median of $390.2 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2022 and 2026: Shares Outstanding (Weighted Average) surged 303.84% in 2022, then declined 1.53% in 2026.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $389.4 million in 2022, then decreased by 0.87% to $386.0 million in 2023, then rose by 1.97% to $393.6 million in 2024, then dropped by 0.86% to $390.2 million in 2025, then dropped by 1.31% to $385.1 million in 2026.
• Business Quant data shows DXCM's Shares Outstanding (Weighted Average) at $385.1 million in Q1 2026, $390.2 million in Q4 2025, and $391.4 million in Q3 2025.